NASDAQ:AMLX | Free Cash Flow | Amylyx Pharmaceuticals, Inc.

Free cash flow is operating cash flow less capital expenditure. FCF / net income requires positive matching-period earnings.

Available history
2021-03-31 to 2026-03-31
Data captured

Historical Free Cash Flow

DateOperating cash flowCapital expenditureFree cash flowFCF / net income
2026-03-31-$36.88M
2025-12-31-$27.9M$86,000.00-$27.99M
2025-03-31-$39.82M$11,000.00-$39.84M
2024-12-31-$59.01M$20,000.00-$59.03M
2024-03-31-$489,000.00$67,000.00-$556,000.00
2023-12-31$13.55M$356,000.00$13.2M278.91%
2023-03-31-$5.07M$250,000.00-$5.32M-338.33%
2022-12-31-$49.7M$620,000.00-$50.32M
2022-03-31-$40.63M$342,000.00-$40.98M
2021-12-31-$28.24M$186,000.00-$28.43M
2021-03-31-$12.64M$14,000.00-$12.66M

Annual Free Cash Flow

DateOperating cash flowCapital expenditureFree cash flowFCF / net income
2025-12-31-$123.34M$138,000.00-$123.48M
2024-12-31-$167.65M$157,000.00-$167.8M
2023-12-31$11.92M$1.24M$10.68M21.67%
2022-12-31-$179.87M$2.53M-$182.4M
2021-12-31-$74.8M$353,000.00-$75.15M